RT Journal Article
SR Electronic
T1 Delayed effects of cigarette graphic warning labels on smoking behavior
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.06.24300835
DO 10.1101/2024.01.06.24300835
A1 Shi, Zhenhao
A1 Wang, An-Li
A1 Audrain-McGovern, Janet
A1 Lynch, Kevin G.
A1 Loughead, James
A1 Langleben, Daniel D.
YR 2024
UL http://medrxiv.org/content/early/2024/01/09/2024.01.06.24300835.abstract
AB Graphic warning labels (GWLs) on cigarette packs are widely employed to communicate smoking-related health risks. Most GWLs elicit high emotional arousal. Our recent study showed lower efficacy of high-arousal GWLs than low-arousal ones during 4 weeks of naturalistic exposure. Here, we conducted a secondary analysis to investigate the delayed effects of GWLs on smoking severity after the end of the 4- week exposure. In 112 adult smokers (56 high-arousal, 56 low-arousal), there was a significant reduction in the number of cigarettes smoked per day (CPD) from immediately post-exposure to 4 weeks post-exposure. The high-arousal and low-arousal groups did not differ in CPD reduction. Our study suggests lasting impact of GWLs on smoking behavior. The finding may be particularly relevant to the high-arousal GWLs, whose efficacy is not as pronounced during direct and continuous exposure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) and the Center for Tobacco Products of the Food and Drug Administration (FDA) under award number R01DA036028 (PI: DDL); NIH/NIDA under award number K01DA051709 (PI: ZS); and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the NIH under award number R00HD084746 (PI: ALW). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the FDA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the University of Pennsylvania Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData produced in the present study are available upon reasonable request.